CN1247222C - Pharmaceutical composition for treating AlDS - Google Patents
Pharmaceutical composition for treating AlDS Download PDFInfo
- Publication number
- CN1247222C CN1247222C CN 03147369 CN03147369A CN1247222C CN 1247222 C CN1247222 C CN 1247222C CN 03147369 CN03147369 CN 03147369 CN 03147369 A CN03147369 A CN 03147369A CN 1247222 C CN1247222 C CN 1247222C
- Authority
- CN
- China
- Prior art keywords
- grams
- medicinal composition
- aids
- present
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicinal composition for treating AlDS, which uses natural plant extracts as medicinal active ingredients. The medicinal composition is prepared from the following raw materials with the proportion by weight: 10 to 50 grams of nysorethorn bark, 5 to 40 grams of liquorice, 5 to 40 grams of safflower, 5 to 40 grams of artemisiae capillaris and 5 to 40 grams of milkvetch root. The medicinal composition of the present invention does not have toxic side effects shown by toxicity tests; the medicinal composition is an effective medicine for resisting AIDS with low cost shown by pharmacodynamics experiments. The medicinal composition treats AIDS by a Chinese type cocktail therapy with multitarget points, so the present invention can resist viruses and can enhance immunological functions. Compared with western medicines, such as AZT, the medicinal composition has the advantages that the present invention can be used for AIDS infected person at the early stage of the onset to prolong periods of the onset.
Description
Technical field
The present invention relates to a kind of by the pharmaceutical composition of natural plant extracts as the treatment acquired immune deficiency syndrome (AIDS) of medicinal active ingredient.
Technical background
Acquired immune deficiency syndrome (AIDS) (Acquired Immunodefiency Syndrome AIDS, acquired immunodeficiency syndrome) be the world today mainly threaten human health can not effect a radical cure one of De Zhi Fu disease.This disease that can not effect a radical cure is rapid spread in the world in a short time, makes the upsurge that has started the research treatment and the medicine that prevents AIDS all over the world, to satisfy clinically the urgent need to the treatment HIV sufferers.Up to the present, though that the inverase that western sciences men develop is approved for is clinical, they are difficult problems that is difficult to overcome to the side effect, particularly skeleton inhibitory action that the patient produces; In addition, from a large amount of synthetics, carry out the screening of anti-HIV, need cost surprising fund, manpower; Find that from Chinese herbal medicine natural HIV (human immunodeficiency virus)-resistant activity chemical compound or guide's thing are importance and the very active fields of studying at present both at home and abroad; theoretical according to the dialectical treatment of Chinese medicine; use Chinese medicine compound and also obtaining certain success aspect the treatment acquired immune deficiency syndrome (AIDS), but its result is not too remarkable.Acquired immune deficiency syndrome (AIDS) is global difficult disease, and it is popular extensively, be in a bad way, prevent difficulty, up to now, not have the way of effecting a radical cure, and two during the last ten years, and whole world medical circle has been carried out unremitting effort to this, has obtained no small achievement.But still there is not breakthrough.The patient of whole world infection has at present reached more than 6,000 ten thousand, China's AIDS the infected has also entered rapid growth period, the problem of preventing and treating in the whole world and China serious day by day, for giving full play to the effect of Chinese medicine in preventing and treating acquired immune deficiency syndrome (AIDS), still do not have at present Chinese medicine preparation carry out normalized, be the international clinical research of being admitted.
Summary of the invention
Purpose of the present invention is intended to the drawback of prior art, provide a kind of by the natural plant medicine be medicinal active ingredient, effectively treat the pharmaceutical composition of acquired immune deficiency syndrome (AIDS).
The pharmaceutical composition of treatment acquired immune deficiency syndrome (AIDS) of the present invention is the medicament of being made by the following weight proportion raw material: Cortex Mori 10-50 gram, Radix Glycyrrhizae 5-40 gram, Flos Carthami 5-40 gram, Herba Artemisiae Scopariae 5-40 gram, Radix Astragali 5-40 gram.
The present invention system adds medically general pharmaceutic adjuvant by above effective medicinal components and is prepared into medically acceptable oral formulations, as: tablet, powder, capsule, oral liquid, soft capsule etc.This drug administration amount is 3-15g every day.
Pharmaceutical composition of the present invention has no side effect through the toxicity test proof, prove that through pharmacodynamic experiment this pharmaceutical composition is the medicine of effective, an inexpensive anti-AIDS, this medicine composite for curing acquired immune deficiency syndrome (AIDS) is the Chinese style HAART of many target spots effect, both antiviral, raise immunity again, compare with Western medicine such as AZT, this pharmaceutical composition AIDSinfected patient at the initial stage of a disease also can be used on one's body, can play the effect that prolongs period of disease.
The pharmaceutical research of this pharmaceutical composition
1, the Study on mechanism of this pharmaceutical composition anti-AIDS
Result of study shows: the mechanism of action of this pharmaceutical composition anti-AIDS can suppress the 55%HIV-1 proteolytic enzyme for suppressing HIV proteolytic enzyme (protease) when 200 μ g/ml, but to reverse transcriptase unrestraint effect.
2, this pharmaceutical composition is to the potentiation research of immunity
Result of study shows: this pharmaceutical composition can strengthen the activity of natural killer cell (natural killing cell), thereby has immunoregulation effect.
3, the inhibition bacterial action of this pharmaceutical composition
Result of study shows: this pharmaceutical composition is inhibited to Cryptococus neooformans, does not kill this bacterium effect but have, and its minimum antibacterial (MIC) is 6.67mg/ml.
The subacute toxicity research of this pharmaceutical composition
By administration is equivalent to one times of clinical medicine dose to rat oral gavage, this pharmaceutical composition of two times, five times was observed 28 days, the inspection of aspects such as tissue, organ, pathology, the result shows that it is to the rat administration after 28 days, tissue, organ, pathology dissection show does not see have unusual and damage, illustrates that on probation is safe to this pharmaceutical composition below patient's gram every days 20.
Clinical trial:
The carrying out of this pharmaceutical composition success I, II phase clinical research, the result shows: this pharmaceutical composition always effectively reaches 89% to HIV sufferers.The III phase of this pharmaceutical composition clinical according to normalized clinical method in the world select on screening patient's in enormous quantities basis that disease meets, virus load and the also standard compliant patient of cd4 cell number participate in, take " double-blind method " in the clinical course, each is to the blood drawing chemical examination of two weeks, after clinical half a year to one year, determine the curative effect of this pharmaceutical composition with statistical method.
The specific embodiment
Embodiment 1:
Get Cortex Mori 35 grams, Radix Glycyrrhizae 20 grams, Flos Carthami 20 grams, Herba Artemisiae Scopariae 20 grams, the Radix Astragali 20 grams, use medicinal alcohol extraction, extract adds common pharmaceutic adjuvant through carbon-18 silica gel column chromatography, makes capsule, obtains this pharmaceutical composition.
Embodiment 2:
Get Cortex Mori 45 grams, Radix Glycyrrhizae 15 grams, Flos Carthami 30 grams, Herba Artemisiae Scopariae 25 grams, the Radix Astragali 20 grams, use medicinal alcohol extraction, extract adds common pharmaceutic adjuvant through carbon-18 silica gel column chromatography, makes powder, obtains this pharmaceutical composition.
Claims (1)
1, a kind of pharmaceutical composition for the treatment of acquired immune deficiency syndrome (AIDS) is characterized in that it being the oral formulations of being made by the following weight proportion raw material: Cortex Mori 10-50 gram, Radix Glycyrrhizae 5-40 gram, Flos Carthami 5-40 gram, Herba Artemisiae Scopariae 5-40 gram, Radix Astragali 5-40 gram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03147369 CN1247222C (en) | 2003-07-11 | 2003-07-11 | Pharmaceutical composition for treating AlDS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03147369 CN1247222C (en) | 2003-07-11 | 2003-07-11 | Pharmaceutical composition for treating AlDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1569090A CN1569090A (en) | 2005-01-26 |
| CN1247222C true CN1247222C (en) | 2006-03-29 |
Family
ID=34471922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03147369 Expired - Fee Related CN1247222C (en) | 2003-07-11 | 2003-07-11 | Pharmaceutical composition for treating AlDS |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1247222C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105708896A (en) * | 2016-04-05 | 2016-06-29 | 黄群德 | Traditional Chinese medicine preparation for treating AIDS (acquired immune deficiency syndrome) |
| CN105770431A (en) * | 2016-05-17 | 2016-07-20 | 唐天东 | Traditional Chinese medicine composition for treating AIDS and preparation method thereof |
-
2003
- 2003-07-11 CN CN 03147369 patent/CN1247222C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1569090A (en) | 2005-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dasgupta | Antiinflammatory herbal supplements | |
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN1483463A (en) | Anti-virus Chinese medicine composition and preparation process thereof | |
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN111097040A (en) | Antiviral lung-heat clearing peptide | |
| CN110772578A (en) | Human body immunity enhancer for preventing and treating cancer and preparation method thereof | |
| CN1140279C (en) | Blood-cleaning pill | |
| Maksimović et al. | Herbal medicinal products in the treatment of osteoarthritis | |
| CN1247222C (en) | Pharmaceutical composition for treating AlDS | |
| WO2005023240A2 (en) | Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto | |
| CN112220846A (en) | Traditional Chinese medicine composition for treating children's chronic cough and application thereof | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| Abbas et al. | Medicinal importance of Nigella sativa Linn [Black seeds] | |
| CN1060048C (en) | Snake spirit for rheumatism and its preparation | |
| CN1270755C (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
| CN1927349A (en) | Traditional Chinese medicine for treating rheumatism and its preparing process | |
| CN1558767A (en) | A pharmaceutical composition made from Chinese traditional medicine for treating snuffle, headache and preparation method thereof | |
| CN1093420C (en) | Process for preparing snuff to treat hepatitis A | |
| CN1177592C (en) | Application of Radix Radix Radix Radix Extract Total Saponins in the Preparation of Drugs for Treating Myocarditis | |
| Roger | Tsobou Roger1*, Hamawa Yougouda2, Fawa Guidawa3, Tatsimo Ndendoung Simplice Joël4, Avana Tientcheu Marie-Louise5, Wouokoue Taffo Junior Baudoin1, Mapongmetsem Pierre Marie3, Van Damme Patrick6 | |
| CN106474297A (en) | Improve pharmaceutical composition of gerontal patient's postoperative cognition disorders and preparation method thereof | |
| WO2006008761A2 (en) | Anti retroviral herbal formulation | |
| CN1093421C (en) | Process for preparing snuff to treat hepatitis B | |
| CN114788859A (en) | Steam equipment multi-vitamin for adjuvant therapy of Acquired Immune Deficiency Syndrome (AIDS), and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: KUMIN SIAIT SCIENCE & TECHNOLOGY Y DEVELOPMENT CO Free format text: FORMER OWNER: WANG LIHONG Effective date: 20060331 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20060331 Address after: 650224 No. 525 Baiyun Road, Yunnan, Kunming (Beijing Road Garden 6-3-202) Patentee after: Kunming Aite company technology development Co. Ltd. Address before: 650224 No. 525 Baiyun Road, Yunnan, Kunming (Beijing Road Garden 6-3-202) Patentee before: Wang Lihong |
|
| ASS | Succession or assignment of patent right |
Owner name: LIU YONG Free format text: FORMER OWNER: KUNMING SIAITE SCIENCE + TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20150123 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150123 Address after: 650224 No. 525 Baiyun Road, Yunnan, Kunming (Beijing Road Garden 6-3-202) Patentee after: Liu Yong Address before: 650224 No. 525 Baiyun Road, Yunnan, Kunming (Beijing Road Garden 6-3-202) Patentee before: Kunming Aite company technology development Co. Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060329 Termination date: 20170711 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |